Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
55
resultados
Última actualización
02/05/2025 [06:45:00]
Resumen de: AU2023367741A1
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
Resumen de: EP4545085A1
The present invention provides therapeutics for Non-Hodgkin Lymphoma. In particular, the present invention provides chimeric antigen receptor (CAR) T-cells that can target CD79b.
Resumen de: AU2023286618A1
The present invention relates to the treatment of subjects having previously untreated follicular lymphoma (FL). More specifically, the invention pertains to the treatment of subjects having previously untreated FL by administering a combination of mosunetuzumab and lenalidomide.
Resumen de: US2025127855A1
A method of treating chronic myelomonocytic leukemia or myelodysplastic syndrome in a subject in need thereof, comprising the steps of: (a) administering intravenously to the subject for the chronic myelomonocytic leukemia about 2.0 mg/kg body weight per day of a recombinant fusion protein of SEQ ID NO: 1 in the form of a composition comprising a pharmaceutically acceptable excipient and the recombinant fusion protein, (b) about 65 minutes to about 75 minutes after completing the administering of step (a), administering subcutaneously to the subject about 75 mg/m2 of azacitidine, and (c) after steps (a) and (b), repeating step (a) once weekly, and administering subcutaneously to the subject about 75 mg/m2 of azacitidine once daily, wherein on the days that the subject is also having step (a) repeated, the azacitidine is administered about 65 minutes to about 75 minutes after completing the repeated administering of step (a).
Resumen de: US2025127751A1
The disclosure belongs to the technical field of medicine, and specifically discloses a traditional Chinese medicine compound preparation for tumors and application thereof. The traditional Chinese medicine compound preparation includes dimethylarsenic acid, indirubin and cordycepin in a concentration ratio of (1-20):(1-10):(1-40). The traditional Chinese medicine compound preparation of the disclosure can be used for treating kinds of tumors, including leukemia, gastric cancer, lung cancer, glioma, papillary thyroid carcinoma, growth hormone adenoma, pituitary adenoma, myeloma, and other malignant tumors. The traditional Chinese medicine compound preparation has significant treatment effect, high safety, and good development prospects.
Resumen de: US2025129435A1
The present disclosure provides a novel method of diagnosing lymphoma, breast cancer, a lymphoma subtype, or a breast cancer subtype in a patient, and kits for implementing the methods.
Resumen de: WO2025085792A1
Disclosed herein are combined therapies for treating a hematologic malignancy (e.g., acute myeloid leukemia (AML), or myelodysplastic syndromes (MDS)), using an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17), and one or more chemotherapeutics, e.g., a Bcl2 inhibitor such as venetoclax, a hypomethylating agent (HMA), or a combination thereof.
Resumen de: WO2025085525A2
The present disclosure provides methods for treating acute myelogenous leukemia (AML) in a subject in need thereof comprising administering to the subject an effective amount of an anti-PD-L1 antibody or antigen binding fragment thereof and cytokine induced memory-like natural killer (CIMN) cells.
Resumen de: WO2025085878A1
The present invention relates to compounds of formula (A) as DUX4 inhibitors for the treatment of e.g. neuromuscular disorders, inflammatory disorders, facioscapulohumeral muscular dystrophy, B-cell leukemia, sarcomas, solid cancers, rheumatoid arthritis, axial spondylarthritis, viral infections, mononucleosis, encephalitis, and varicella. Exemplary compounds are e.g.
Resumen de: US2025127755A1
Disclosed herein are methods for using an antimalarial endoperoxide compound, such as artemisinin, in treating a subject suffering from myelodysplastic syndromes (MDS), and hi slowing or preventing the progression of MDS in the subject to development of acute myeloid leukemia (AML).
Resumen de: US2025129431A1
The invention features methods for the identification of genomic aberrations in circulating tumor cells (CTCs) isolated from peripheral blood. In various embodiments of the disclosure, the methods involve isolation of a small number of purified circulating multiple myeloma cells, purification of genomic DNA from the cells, and sequencing of the genomic DNA.
Resumen de: WO2025081518A1
Provided is the use of DPP4 as an NK/T cell lymphoma tumor marker, the use of a DPP4 detection reagent in preparing a kit for screening for NK/T cell lymphoma, and the use of a DPP4 inhibitor in preparing a medicine for treating NK/T cell lymphoma.
Resumen de: US2025129162A1
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
Resumen de: US2025129420A1
There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.
Resumen de: CN119365214A
Methods of treating diffuse large B-cell lymphoma (DLBCL) or increasing, enhancing, or stimulating an immune response with antibodies and antigen-binding fragments thereof that specifically bind to TIGIT (T cell immune receptors with Ig and ITIM domains) in combination with an anti-PD1 antibody and/or an anti-CD20 antibody are provided.
Resumen de: AU2022476674A1
The present disclosure relates generally to methods of treating T-cell lymphomas with combination therapies.
Resumen de: US2025123282A1
Disclosed here are methods of evaluating resistance to a tyrosine kinase inhibitor (TKI) therapy of acute myeloid leukemia (AML) in a subject that include detecting the status of CD33, CD44, and phosphorylated BCL2 associated agonist of cell death (pBAD) expression. Also disclosed herein are methods of treating AML in a subject by administering a TKI and one or more inhibitors targeting a TKI-activated compensation pathway to the subject.
Resumen de: US2025120947A1
The present invention generally relates to sensitizer compounds and their use to sensitize cancer and/or pre-cancerous cells of certain cancers to treatment with certain resistance-prone therapeutics used in cancer therapy. In embodiments, the conjugates of particular esters or amides of Near Infrared Dyes, are used as sensitizers to avoid or overcome therapeutic resistance once formed. In embodiments, the sensitizers include conjugates with Cisplatin, Simvastatin, Artemisinin, platin-based compounds or statins. In embodiments, the resistance prone cancer therapeutics include cisplatin, gemcitabine, doxorubicin, paclitaxel, docetaxel, and platin-based compounds. These may be administered in combination with the sensitizer, or the sensitizer itself may comprise an therapeutci-derived moiety conjugated to the sensitizer, for example as is the case for dye-CIS conjugated sensitizers. Alternatively, the sensitizer may be co-administered with one or more therapeutic. Embodiments of the invention may advantageously be used in cancers that have a tendency to develop resistance to such cancer therapeutics and/or to form metastases, including e.g. lung, pancreatic, prostate, testicular, ovarian, cervical, bladder, breast, head and neck, esophageal, and stomach, cancers, germ cell tumors, lymphomas and other cancers.
Resumen de: US2025121001A1
A method of enhancing embryo implantation in a subject is disclosed which comprises administering to the uterine cavity of the subject a formulation comprising copper and/or zinc in an amount effective to stimulate endometrial production of leukaemia inhibitory factor (LIF) and/or vascular endothelial growth factor (VEGF). Alternatively, a device may be inserted into the uterine cavity of the subject, wherein the device comprises copper and/or zinc, for a period of time that is effective to stimulate endometrial production of LIF and/or VEGF. The method is suitable for use with women undergoing treatment by any of the assisted reproductive technologies, such as those involving the transfer of embryos such as in vitro fertilisation (IVF) and variants including IVF-ICSI (intracytoplasmic sperm injection) and in vitro maturation (IVM) treatments, as well as intrauterine-insemination (IUI) therapy. However, the method is also applicable for women wanting to improve their prospects of pregnancy through natural conception.
Resumen de: US2025122300A1
Isolated anti-human CD45RC antibodies or binding fragments thereof, nucleic acids and expression vector encoding the same, compositions including the same, and uses thereof as medicaments, including for the prevention and/or treatment of CD45RChigh-related diseases (including autoimmune diseases, undesired immune responses, monogenic diseases, and lymphoma or cancer), in particular for use in preventing and/or treating graft-versus-host disease (GVHD).
Resumen de: US2025122297A1
Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and an immunomodulatory drug (e.g. pomalidomide or lenalidomide). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).
Resumen de: US2025122295A1
The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib. In some embodiments, the agent binds to a receptor involved in signalling by at least one of IL-3, G-CSF and GM-CSF. In some embodiments, the agent is a mutein selected from the group consisting of IL-3 muteins, G-CSF muteins and GM-CSF muteins. In some embodiments, the mutein is an IL-3 mutein. In some embodiments, the agent is a soluble receptor which is capable of binding to IL-3.
Resumen de: WO2025080282A1
The present disclosure provides methods for treating leukemia (e.g., AML) using a CLK/DYRK inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor (e.g., venetoclax). Kits for use in practicing the methods are also provided.
Resumen de: WO2025080543A1
Provided herein are methods of predicting the responsiveness of a lymphoma patient to a cancer treatment. Also provided herein are methods of treating a lymphoma patient based on predicting the responsiveness of the lymphoma patient to a cancer treatment.
Nº publicación: WO2025080924A1 17/04/2025
Solicitante:
THE TRUSTEES OF THE UNIV OF PENNSYLVANIA [US]
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Resumen de: WO2025080924A1
Provided herein is a recombinant adeno-associated virus (rAAV) comprising an AAV capsid and an expression cassette comprising an engineered nucleic acid sequence encoding an anti-hCD20 antibody (i.e., rituximab) comprising heavy chain and light chain operably linked to regulatory control sequences which direct expression of rituximab in a target cell. Also provided are a pharmaceutical composition comprising a rAAV as described herein in a formulation buffer, nucleic acid molecule, packaging host cells, rAAV production system, and a method of treating CD20-positive central nervous system lymphomas
BOPI
Sede Electrónica
